Lynn Anne Bristol

Array ( [id] => 10306534 [patent_doc_number] => 20150191534 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-09 [patent_title] => 'HUMAN ANTIBODIES TO HUMAN DELTA LIKE LIGAND 4' [patent_app_type] => utility [patent_app_number] => 14/524164 [patent_app_country] => US [patent_app_date] => 2014-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15940 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14524164 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10567422 [patent_doc_number] => 09290578 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-22 [patent_title] => 'Anti-Ly6E antibodies and methods of use' [patent_app_type] => utility [patent_app_number] => 14/518294 [patent_app_country] => US [patent_app_date] => 2014-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 32 [patent_no_of_words] => 26727 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14518294 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10209466 [patent_doc_number] => 20150094456 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-02 [patent_title] => 'Anthracycline-Antibody Conjugates for Cancer Therapy' [patent_app_type] => utility [patent_app_number] => 14/516770 [patent_app_country] => US [patent_app_date] => 2014-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 19059 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14516770 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17975560 [patent_doc_number] => 11492408 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-08 [patent_title] => Bi-specific T-cell engager specific for BCMA [patent_app_type] => utility [patent_app_number] => 15/028113 [patent_app_country] => US [patent_app_date] => 2014-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 15 [patent_no_of_words] => 6284 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15028113 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11122059 [patent_doc_number] => 20160319032 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-03 [patent_title] => 'METHODS OF TREATING AND DIAGNOSING ALPHA-V-BETA-6 OVEREXPRESSING CANCER' [patent_app_type] => utility [patent_app_number] => 15/026350 [patent_app_country] => US [patent_app_date] => 2014-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 42844 [patent_no_of_claims] => 75 [patent_no_of_ind_claims] => 58 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15026350 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10974745 [patent_doc_number] => 20140377781 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-12-25 [patent_title] => 'Anti-Claudin 3 Monoclonal Antibody and Treatment and Diagnosis of Cancer Using the Same' [patent_app_type] => utility [patent_app_number] => 14/482731 [patent_app_country] => US [patent_app_date] => 2014-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 29267 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14482731 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11011044 [patent_doc_number] => 20160207996 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-21 [patent_title] => 'ANTIBODIES TO COMPLEX TARGETS' [patent_app_type] => utility [patent_app_number] => 14/913984 [patent_app_country] => US [patent_app_date] => 2014-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 44 [patent_no_of_words] => 51668 [patent_no_of_claims] => 52 [patent_no_of_ind_claims] => 31 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14913984 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11107648 [patent_doc_number] => 20160304618 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-20 [patent_title] => 'ANTIBODIES FOR DIAGNOSIS OF ACUTE MYELOID LEUKEMIA' [patent_app_type] => utility [patent_app_number] => 14/913843 [patent_app_country] => US [patent_app_date] => 2014-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 6167 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14913843 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14821035 [patent_doc_number] => 10407509 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-09-10 [patent_title] => NTRK2 fusions [patent_app_type] => utility [patent_app_number] => 14/909040 [patent_app_country] => US [patent_app_date] => 2014-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 13766 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14909040 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17193165 [patent_doc_number] => 11161906 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-02 [patent_title] => Multispecific antibodies, multispecific activatable antibodies and methods of using the same [patent_app_type] => utility [patent_app_number] => 14/340872 [patent_app_country] => US [patent_app_date] => 2014-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 38 [patent_no_of_words] => 58927 [patent_no_of_claims] => 45 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14340872 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10516031 [patent_doc_number] => 09243069 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-01-26 [patent_title] => 'HER2/neu-specific antibodies and methods of using the same' [patent_app_type] => utility [patent_app_number] => 14/332239 [patent_app_country] => US [patent_app_date] => 2014-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 13 [patent_no_of_words] => 32294 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14332239 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10806565 [patent_doc_number] => 20160152724 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-02 [patent_title] => 'A NEW FUSION PROTEIN TO TARGET AND TREAT ACUTE MYLOID LEUKEMIA CELLS' [patent_app_type] => utility [patent_app_number] => 14/901016 [patent_app_country] => US [patent_app_date] => 2014-07-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 9024 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14901016 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10784170 [patent_doc_number] => 20160130326 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-12 [patent_title] => 'NOVEL ANTIBODY FRAMEWORKS' [patent_app_type] => utility [patent_app_number] => 14/900550 [patent_app_country] => US [patent_app_date] => 2014-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 11722 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14900550 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9785196 [patent_doc_number] => 20140302016 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-09 [patent_title] => 'BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, THAT SPECIFICALLY BIND CD154 AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/309118 [patent_app_country] => US [patent_app_date] => 2014-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 37 [patent_no_of_words] => 45251 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14309118 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10953335 [patent_doc_number] => 20140356355 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-12-04 [patent_title] => 'IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS' [patent_app_type] => utility [patent_app_number] => 14/304472 [patent_app_country] => US [patent_app_date] => 2014-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 81352 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14304472 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13763565 [patent_doc_number] => 10174117 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-01-08 [patent_title] => Anti-HER2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer [patent_app_type] => utility [patent_app_number] => 14/897122 [patent_app_country] => US [patent_app_date] => 2014-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 7 [patent_no_of_words] => 9961 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14897122 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9785238 [patent_doc_number] => 20140302058 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-09 [patent_title] => 'HUMAN ANTI IL-6 ANTIBODIES WITH EXTENDED IN VIVO HALF-LIFE AND THEIR USE IN TREATMENT OF ONCOLOGY, AUTOIMMUNE DISEASES AND INFLAMMATORY DISEASES' [patent_app_type] => utility [patent_app_number] => 14/253161 [patent_app_country] => US [patent_app_date] => 2014-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 79852 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14253161 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9698581 [patent_doc_number] => 20140248267 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-04 [patent_title] => 'ANTI-CD33 ANTIBODIES AND METHODS FOR TREATMENT OF ACUTE MYELOID LEUKEMIA USING THE SAME' [patent_app_type] => utility [patent_app_number] => 14/249602 [patent_app_country] => US [patent_app_date] => 2014-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 18425 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14249602 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10945784 [patent_doc_number] => 20140348805 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-11-27 [patent_title] => 'HIGH AFFINITY T CELL RECEPTOR AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 14/224525 [patent_app_country] => US [patent_app_date] => 2014-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 13067 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14224525 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10663680 [patent_doc_number] => 20160009824 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-14 [patent_title] => 'TETRAVALENT BISPECIFIC ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/777152 [patent_app_country] => US [patent_app_date] => 2014-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 22342 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14777152 [rel_patent_id] =>[rel_patent_doc_number] =>)